Stockscreener 앱 받기
3.70
0.80%
-0.03
시간 외 거래:
3.77
0.07
+1.89%
전일 마감가:
$3.73
열려 있는:
$3.69
하루 거래량:
307.54K
Relative Volume:
0.65
시가총액:
$44.27M
수익:
$12,000
순이익/손실:
$-48.50M
주가수익비율:
-0.2168
EPS:
-17.0687
순현금흐름:
$-19.78M
1주 성능:
-5.37%
1개월 성능:
-6.57%
6개월 성능:
-70.01%
1년 성능:
-43.84%
1일 변동 폭
$3.666
$3.95
1주일 범위
$3.6301
$4.17
52주 변동 폭
$2.49
$49.80
Incannex Healthcare Inc Stock (IXHL) Company Profile
명칭
Incannex Healthcare Inc
전화
61 409 840 786
주소
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
3.70 | 43.91M | 12,000 | -48.50M | -19.78M | -17.07 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
IXHL Forecast — Price Target — Prediction for 2027 - TradingView
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
IXHL Should I Buy - Intellectia AI
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Healthcare receives A$6m R&D tax incentive payment - Investing.com UK
Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com - Investing.com Nigeria
Incannex Healthcare Secures Major Non-Dilutive R&D Funding - TipRanks
Incannex Healthcare Secures Over A$11 Million in Non-Dilutive Capital Through Australian R&D Tax Incentive Program - Quiver Quantitative
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility - The Manila Times
Incannex lines up A$11m in non‑dilutive cash to advance IHL‑42X study - Stock Titan
Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding - TradingView
Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan
Incannex Healthcare: Target Price Consensus and Analysts Recommendations | IQI | AU000000IHL8 - marketscreener.com
Incannex Healthcare Gains Independent Buy-Rated Research Coverage - TipRanks
Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan
Incannex Healthcare: Alliance Global Partners Starts Coverage with $18 Price Target - TradingView
Alliance Global initiates Incannex (IXHL) equity research coverage on key drug pipeline - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
$Incannex Healthcare (IXHL.US)$ [Onlooker][OK] - Moomoo
INCANNEX HEALTHCARE INC (IXHL) Stock Chart - ChartMill
Incannex Healthcare Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D InvestmentOperating Income Trends - newsline.com
Why Are ASX Cannabis Stocks Drawing Fresh Attention? - Kalkine Media
IXHL Q1 2026 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - newsline.com
Incannex Healthcare (IXHL) Dips 3.27% as Stock Tests Near-Term SupportCall Wall - newsline.com
Incannex Healthcare | 8-K: Current report - Moomoo
Incannex Shares Surge Following Promising Sleep Apnea Trial Data - MSN
Incannex reactivates share repurchase program, cites ‘significant disconnect’ between its market cap and financial strength - MSN
IXHL Technical Analysis | Trend, Signals & Chart Patterns | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill
Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA - Sleep Review
Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary - TradingView
IXHL: Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases - TradingView
Incannex Healthcare (NASDAQ: IXHL) grows cash to $74.5M amid $16.8M loss - Stock Titan
Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea - TradingView
Incannex launches DReAMzz study for sleep apnea treatment - Investing.com UK
Incannex Healthcare Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea, Advancing Late-Stage Development 1 - Minichart
Incannex launches DReAMzz study for sleep apnea treatment By Investing.com - Investing.com South Africa
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea - The Manila Times
Incannex Healthcare Inc. Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Treatment - Quiver Quantitative
New sleep apnea drug enters dose-test in Incannex DReAMzz trial - Stock Titan
Incannex Launches DReAMzz Study for IHL-42X Sleep Apnea - TipRanks
Incannex Healthcare commences DReAMzz study for IHL-42X, 14 sites onboarded - TradingView
Incannex (IXHL) launches DReAMzz dose-optimization study of IHL-42X for sleep apnea - Stock Titan
IXHL Q3'26 Earnings: EPS estimate is (0.60) USD - TradingView
Incannex Healthcare Inc (IXHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
1.13%
자본화:
|
볼륨(24시간):